Could a combo eye treatment cut down on needle pokes?
NCT ID NCT01295112
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether adding a dexamethasone implant (Ozurdex) to standard bevacizumab (Avastin) eye injections could reduce the number of injections needed for people with non-ischemic central retinal vein occlusion. Sixty-eight participants received either Avastin plus a sham procedure or Avastin plus Ozurdex. The main goal was to count how many Avastin injections were needed over 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bevacizumab (Avastin) and dexamethasone (Ozurdex) eye implants/injections
- What this could lead to
- If it works, this could mean fewer eye injections for people with central retinal vein occlusion, making treatment easier.
- What could go wrong
- This is a small, completed Phase 2/3 trial with only 68 participants, so results may not apply to everyone. Adding Ozurdex may not reduce injections enough or could cause side effects like increased eye pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas Retina Associates
Dallas, Texas, 75231, United States